Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study

Supportive Care in Cancer

Volumn 22, Issue 10, 2014, Pages 2831-2837

  Linot, B ^a   Augereau, P ^a   Breheret, R ^b   Laccourreye, L ^b   Capitain, O ^a  

^a UMR INSERM U892 CNRS 6299   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

5 Fluorouracil; Cisplatin; Docetaxel; Febrile neutropenia; G CSF; Head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

AGED; CLINICAL PROTOCOL; DRUG COMBINATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84930510701     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2270-8     Document Type: Article

References (23)

1. Sturgis EM (2011) The International Head and Neck Cancer Epidemiology consortium. Head Neck 33(1):141
2. Zorat PL, Paccagnella A, Cavaniglia G et al (2004) Randomized phase III trial of neoadjuvant chemotherapy in head and neck: 10 year follow up. J Natl Cancer Inst 94:1714–1717
3. Lorch JH, Posner MR, Wirth LJ et al (2008) Induction chemotherapy in locally advanced head and neck cancer. A new standard of care? Hematol Oncol Clin N Am 22:115–163
4. Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506
5. Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522
6. Hitt R, Grau JJ, Lopez-Pousa A et al (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 27 (15 suppl abstr 6009)
7. Bonnin N, Ceruse P, Bachelot T, et al (2008) Efficacy of neoadjuvant TPF (nTPF; docetaxel, T; cisplatin, P; 5FU) in nonselected patients (pts) with head and neck cancer and subsequent radiotherapy (RT) combined with chemotherapy (CT) or cetuximab (Cx). J Clin Oncol 26 (suppl2 0, abstr 6074).
8. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715
9. Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704
10. Paccagnella A, Mastromauro C, D’Amanzo P, Ghi M (2010) G. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Oncologist 15:8–12
11. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205
12. Crawford J, Althaus B, Armitage J et al (2007) National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 5:188–202
13. Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J Clin Oncol 20:727–731
14. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46
15. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267
16. Hoffman PS (2005) Administration of pegfilgrastim on the same-day or next-day of chemotherapy. J Clin Oncol 23 (Suppl 16, Abstr 8137).
17. Belani CP, RamalingamS, Al-janadi A, et al (2006) A randomized double-blind phase 2 study to evaluate same-day vs. next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. J Clin Oncol 24 (Suppl 18, Abstr 7110).
18. Lokich J (2005) Same-day pegfilgrastim and chemotherapy. Cancer Investig 23:573–576
19. Shuman I, Lambrou N, Robson K et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228
20. Matthews KS, Shipman KA et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112(3):601–604
21. Saven A, Schwartzberg L, Kaywin P, et al (2006) Randomized double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients. J Clin Oncol 24 (suppl 18, Abstr 7570).
22. Lokich JJ (2006) Same-day pegfilgrastim and CHOP chemotherapy for non Hodgkin lymphoma. Am J Clin Oncol 29:361–363
23. Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32